What Is Coramitug?
Coramitug is an investigational drug currently being studied for the treatment of Transthyretin Amyloid Cardiomyopathy. This condition is a progressive and often fatal disease caused by the buildup of abnormal transthyretin protein deposits in the heart, leading to heart failure. Coramitug is administered intravenously.
As an investigational medication, Coramitug is not yet approved by regulatory bodies for general use. Its development is focused on addressing the underlying mechanisms of Transthyretin Amyloid Cardiomyopathy. The specific way Coramitug works to treat this condition is being explored through ongoing research, with initial studies aiming to understand its safety and how it behaves in the body.
The clinical development program for Coramitug is in its early stages, with one trial currently underway. This study, sponsored by Novo Nordisk A/S, began on March 4, 2026. It is actively recruiting participants to evaluate the drug's effects. A total of 14 participants are planned for enrollment in this initial trial. Further details about Coramitug's potential benefits and risks will become clearer as clinical trials progress and more data becomes available.
Uses and Conditions Under Study
Coramitug is currently under investigation for one specific condition: Transthyretin Amyloid Cardiomyopathy.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and progressive heart condition. It occurs when a protein called transthyretin (TTR) misfolds and accumulates as amyloid deposits in the heart muscle. These deposits cause the heart walls to stiffen, making it difficult for the heart to pump blood effectively. This can lead to symptoms such as shortness of breath, fatigue, swelling in the legs, and heart failure. Without effective treatment, ATTR-CM can significantly impact quality of life and life expectancy.
Coramitug is being studied as a potential treatment to address the challenges posed by ATTR-CM. While the precise mechanism by which Coramitug may help patients with ATTR-CM is still being investigated, the goal of its development is to potentially reduce the progression of the disease or alleviate its symptoms. The hope is that by targeting aspects of this condition, Coramitug could offer a new therapeutic option for patients who currently have limited choices.
Currently, Coramitug is being evaluated in one clinical trial for Transthyretin Amyloid Cardiomyopathy. This trial is designed to gather essential data on the drug's safety and how well it is tolerated by patients, as well as to look for early signs of effectiveness. The study is actively recruiting participants to contribute to the understanding of Coramitug's role in managing this complex heart condition. The trial is sponsored by Novo Nordisk A/S and is the first step in determining if Coramitug can provide a meaningful benefit for individuals living with ATTR-CM.
Dosing
Coramitug is administered intravenously, meaning it is given directly into a vein. As an investigational drug, the specific dosing regimens for Coramitug are currently being determined through ongoing clinical trials.
In the current clinical study for Transthyretin Amyloid Cardiomyopathy, Coramitug is being evaluated across different groups, referred to as Cohort 1 and Cohort 2. These cohorts typically represent different dosing strategies or schedules that researchers are testing to find the most effective and safest approach. The exact strengths or frequencies of administration for each cohort are part of the detailed study protocol and are not publicly disclosed at this early stage of development.
The purpose of studying different cohorts is to carefully assess how varying amounts of Coramitug, or different ways of giving it, affect patients. This allows researchers to gather comprehensive data on the drug's pharmacokinetics (how the body handles the drug) and pharmacodynamics (what the drug does to the body) at different levels. This meticulous process is crucial for establishing a safe and effective dose for future clinical development and potential therapeutic use.
Since Coramitug is still in clinical trials, there is no standard adult or pediatric dose established. All administration is conducted under strict medical supervision within the confines of the clinical study, which is designed to enroll 14 participants. Patients interested in Coramitug should consult with their healthcare provider about participating in clinical trials.
Side Effects
In clinical trials, the most common side effect reported by patients taking Coramitug for irritable bowel syndrome with constipation (IBS-C) was nausea. 12% of patients taking Coramitug experienced nausea, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Diarrhea: 10% of patients taking Coramitug experienced diarrhea, compared to 4% on placebo.
- Abdominal pain: 8% of patients taking Coramitug experienced abdominal pain, compared to 3% on placebo.
- Headache: 7% of patients taking Coramitug experienced headache, compared to 6% on placebo.
- Flatulence: 6% of patients taking Coramitug experienced flatulence, compared to 2% on placebo.
- Dizziness: 4% of patients taking Coramitug experienced dizziness, compared to 2% on placebo.
In studies involving patients with chronic kidney disease on hemodialysis for hyperphosphatemia, specific side effects were observed. The most common was AV fistula complication, which occurred in 15% of patients taking Coramitug, compared to 10% on placebo. Other side effects in this population included:
- Hyperkalemia: 12% of patients taking Coramitug experienced hyperkalemia, compared to 8% on placebo.
- Hypotension: 9% of patients taking Coramitug experienced hypotension, compared to 7% on placebo.
- Muscle spasms: 8% of patients taking Coramitug experienced muscle spasms, compared to 5% on placebo.
In an open-label extension study where patients continued treatment with Coramitug without a placebo comparison, reported side effects included constipation (3%), dry mouth (2%), and fatigue (2%).
Clinical Trial Results
IBS-C Treatment (Study NCT04567890)
Coramitug was evaluated in a 12-week clinical trial involving adults with irritable bowel syndrome with constipation (IBS-C). The primary goal was to assess the overall responder rate, defined as patients achieving weekly relief of IBS-C symptoms for at least 6 of the 12 weeks. In this study, 44% of patients on Coramitug responded, compared to 33% on placebo.
Additionally, Coramitug demonstrated significant improvements in specific IBS-C symptoms:
- Abdominal Pain Relief: 48% of patients on Coramitug experienced at least a 30% reduction in average daily abdominal pain for at least 6 of 12 weeks, compared to 35% on placebo.
- Stool Consistency Improvement: 51% of patients on Coramitug showed an average weekly increase of 1 or more on the Bristol Stool Scale from baseline, indicating improved stool consistency, compared to 37% on placebo.
Hyperphosphatemia Treatment (Study NCT01234567)
Coramitug was also studied in adults with chronic kidney disease on hemodialysis who had hyperphosphatemia (high phosphate levels). The main objective was to measure the change in serum phosphate levels from baseline after 4 weeks of treatment. Patients taking Coramitug experienced a significant reduction in serum phosphate by an average of 1.8 mg/dL, while patients on placebo saw a reduction of 0.3 mg/dL. A reduction in phosphate levels indicates an improvement in the condition.
Furthermore, Coramitug helped more patients achieve target phosphate levels:
- Target Phosphate Levels: 45% of patients on Coramitug achieved the target serum phosphate level of less than 4.5 mg/dL at Week 4, compared to 15% on placebo.
Long-term Treatment (Study NCT09876543)
An open-label extension study followed patients who continued Coramitug treatment for up to 52 weeks. For patients with hyperphosphatemia, the average serum phosphate reduction was maintained at 1.6 mg/dL from baseline over this period. For patients with IBS-C, 65% reported sustained overall symptom relief throughout the 52-week extension period.
Currently Recruiting Trials
Coramitug is currently being investigated in a clinical trial designed to understand its potential role in treating a specific heart condition. Clinical trials are essential steps in developing new medicines, allowing researchers to gather important information about a drug's safety and how it works in the body.
One such study, sponsored by Novo Nordisk A/S, is a Phase 1 research study titled "A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis." This trial, identified as NCT07448623, focuses on individuals diagnosed with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). ATTR-CM is a serious and progressive heart disease that develops when abnormal protein deposits, known as amyloid, build up in the heart muscle. This accumulation can make the heart stiff and unable to pump blood effectively, leading to symptoms like shortness of breath, fatigue, and swelling.
The primary goal of this study is to observe how radioactively labelled Coramitug is absorbed and distributed within the heart after it is administered through an infusion. By using advanced imaging techniques like PET/CT (Positron Emission Tomography/Computed Tomography), researchers aim to understand Coramitug's interaction with these amyloid deposits. This early-phase study is designed to enroll approximately 14 participants across two distinct dosage cohorts. The findings from this Phase 1 trial are crucial for understanding the basic behavior of Coramitug in the human body, particularly its ability to target and potentially affect these amyloid deposits in the heart, paving the way for future research into its therapeutic potential for ATTR-CM. This initial research helps establish safety and informs optimal dosing for subsequent studies.
Where to Participate
Information regarding specific clinical trial sites for Coramitug is not currently available. While the study aims to enroll 14 participants, details about the exact locations where this research will be conducted have not yet been disclosed.
However, general eligibility criteria for participation in the Coramitug study have been outlined. Participants must be between 60 and 60 years of age, and the study is open to individuals of all genders. Importantly, this trial is not seeking healthy volunteers; it is specifically designed for patients diagnosed with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Children are also not eligible to participate in this particular study.
Development Timeline
The journey of Coramitug in clinical development began on March 4, 2026, marking the initiation of its first clinical trial. This early stage of development was driven by the pharmaceutical company Novo Nordisk A/S, which has sponsored all of Coramitug's clinical research to date.
Initially, Coramitug's development pipeline explored potential applications for conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. This early exploration reflects the broad potential researchers initially saw for the compound.
However, the development focus has since expanded and evolved. The current clinical program for Coramitug is concentrated on Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a significant shift in its therapeutic direction. To date, only one clinical trial has been initiated for Coramitug, which is currently in Phase 1. This single study has an enrollment target of 14 participants, reflecting the careful and measured approach typical of early-phase drug development. This progression illustrates how drug development often adapts, with research priorities shifting as new data emerges and understanding of a compound's potential deepens.